Search clinical trials for: programmed death ligand 1 (PD-L1)

Total 52155 results

Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

Small Cell Lung Cancer (SCLC)

United States, Australia, Canada, Chile, France, Germany, Hungary, Ireland, Israel, Japan, Korea, Republic of, New Zealand, Poland, Russian Federation, Spain, Switzerland, Taiwan, Turkey, United Kingdom
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Junling Li

Recruiting

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Advanced Non Squamous NSCLC

China
NYU Langone Health
Bristol-Myers Squibb

Completed

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Melanoma

United States
University of Leipzig

Recruiting

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (CaPture)

Hepatocellular Carcinoma

Germany
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, France, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Shanghai Zhongshan Hospital

Recruiting

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

Hepatocellular Carcinoma

China
IO Biotech
Merck Sharp & Dohme LLC

Completed

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

NSCLC

United Kingdom, Germany, Netherlands, Spain
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC (LungCadX)

NSCLC

China
Merck Sharp & Dohme LLC
European Organisation for Research and Treatment of Cancer

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)

Melanoma
Fondazione Ricerca Traslazionale

Unknown

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC) (PD-L1)

To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods
First Affiliated Hospital of Harbin Medical University

Not yet recruiting

Effect of Combination Therapy on SCLC After Initial Treatment Failure

Small-cell Lung Cancer
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
Sohag University

Not yet recruiting

Expression of Programmed Death Ligand-1 (PD-L1) in Nasopharyngeal and Hyypopharyngeal Carcinoma

Nasopharyngeal and Hypopharyngeal Carcinoma

Egypt
Novartis Pharmaceuticals

Active, not recruiting

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Advanced Solid Tumors | Triple Negative Breast Cancer | Chordoma and Alveolar Soft Part Sarcoma

United States, Taiwan, Spain, Canada, Singapore, Italy, Japan, Israel, France
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Lene Meldgaard Knudsen
IO Biotech

Terminated

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma

Denmark
Effector Therapeutics

Completed

Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy

Solid Tumors

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Marker Therapeutics, Inc.

Completed

TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

United States
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Uterine Cervical Neoplasms

Canada, United States, Australia, Austria, Belgium, Brazil, Chile, China, Colombia, Czechia, France, Germany, Greece, Guatemala, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Norway, Peru, Russian Federation, Spain, Sweden, ... and more
Shanghai International Medical Center

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)

Advanced Solid Tumor | PD-1 Antibody | CAR-T Cells

China
Naestved Hospital

Recruiting

Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.

Non-small Cell Lung Cancer | Malignant Pleural Effusion

Denmark
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Cancer Research UK
Heptares Therapeutics Limited

Recruiting

HTL0039732 in Participants With Advanced Solid Tumours

Sarcoma | Neoplasms | Kidney Neoplasms | Uterine Cervical Neoplasms | Stomach Neoplasms | Head and Neck Neoplasms | Lung Neoplasms | Urinary Bladder Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Esophageal Neoplasms | Mesothelioma, Malignant | Prostatic Neoplasms, Castration-Resistant | Pheochromocytomas

United Kingdom
Groupe Hospitalier Pitie-Salpetriere
Vanderbilt University Medical Center; Vanderbilt University; Institute of Cardiometabolism...

Completed

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions (RAFALE)

Myocarditis | Cardiac Complication

France
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency

United States
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma
Novartis Pharmaceuticals

Completed

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Melanoma | Triple Negative Breast Cancer | Anaplastic Thyroid Cancer | Other Solid Tumors | Non-small Sell Lung Cancer (NSCLC)

United States, Italy, Spain, Hungary, Taiwan, Germany, Netherlands, France, Norway, Poland, Thailand, Lebanon, Turkey, Canada
Incyte Corporation

Withdrawn

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Non-small Cell Lung Cancer
Hunan Cancer Hospital
Xiangya Hospital of Central South University; Innovent Biologics (Suzhou) Co...

Unknown

Assessing Safety and Efficacy of Sintilimab and Metformin Combination Therapy in SCLC

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

China
Bristol-Myers Squibb

Withdrawn

Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy

Multiple Myeloma | Hodgkin Lymphoma | Non-Hodgkin's Lymphoma | Chronic Myelogenous Leukemia
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

Cervical Cancer | Advanced Solid Tumor

China
Case Comprehensive Cancer Center

Completed

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

Metastatic Renal Cell Cancer

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Qilu Hospital of Shandong University

Withdrawn

Neoadjuvant Immunotherapy to ESCC

Esophagus SCC

China
Merck Sharp & Dohme LLC

Completed

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

Head and Neck Squamous Cell Cancer
Maastricht Radiation Oncology

Completed

Immune Profiling After HDR in Local Relapsed Prostate Cancer (PRIMUS)

Prostate Cancer | PD-L1

Netherlands
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor

Advanced Malignancies | PD-1 Antibody | CAR-T Cells

China
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

Carcinoma, Renal Cell

Poland, Australia, Japan, United States, Korea, Republic of, Taiwan, China, Brazil, Bulgaria, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Malaysia, Mexico, Netherlands, New Zealand, Romani... and more
Sarah Goldberg
Mirati Therapeutics Inc.

Terminated

Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC

Lung Diseases | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Metastatic Lung Non-Small Cell Carcinoma | PD-L1 Gene Mutation | Pembrolizumab | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Advanced Treatment-Naïve PD-L1 | Sitravatinib

United States
Merck Sharp & Dohme LLC

Completed

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Austria, Brazil, France, Israel, Korea, Republic of, Norway, Spain, United Kingdom
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Colorectal Neoplasms

United States, Canada
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)

Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer
Merck Sharp & Dohme LLC

Completed

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Neoplasms | Carcinoma, Non-Small-Cell Lung
Checkpoint Therapeutics, Inc.
Novotech (Australia) Pty Limited

Recruiting

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Non Hodgkin Lymphoma | Endometrial Cancer | Carcinoma, Small Cell | Urothelial Carcinoma | Classical Hodgkin Lymphoma | Merkel Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Malignant Mesothelioma, Advanced

Australia, New Zealand, Thailand, Ukraine, Spain, Russian Federation, France, Poland, South Africa
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

Gastric Adenocarcinoma
Yale University

Terminated

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

Asymptomatic Myeloma

United States
Maxinovel Pty., Ltd.

Recruiting

MAX-10181 in Patients With Advanced Solid Tumor (PD-L1)

Solid Tumor

China

Search clinical trials for: programmed death ligand 1 (PD-L1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations